



#5  
10/24/02  
89

VPI/98-19 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned  
Group Art Unit : 1646  
Applicants : David Lauffer, et al.  
Application No.: 10/039,898 ✓  
Filed : January 3, 2002 ✓  
For : CYCLIZED AMINO ACID DERIVATIVES

TECH CENTER 1600/2900

OCT 22 2002

RECEIVED

Cambridge, Massachusetts  
October 15, 2002

Hon. Commissioner  
for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.56 AND 1.97

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants,  
through their attorney, make of record the documents  
listed below.

Foreign Patent Documents

Cit e No.	Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication
B1	WO 97/16446	Merck Sharp & Dohme Limited	09-May-1997
B2	WO 97/16190	Guilford Pharmaceuticals, Inc.	09-May-1997
B3	WO 96/41609	Vertex Pharmaceuticals Incorporated	27-Dec-1996
B4	O 289 227 A1	Syntex Pharma Ltd.	02-Nov-1988

Non-Patent Documents

Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
C1	Hori, M., et al., "N-(1,2-Diphenylethyl)piperazines," retrieved from STN Database accession no. 85:33075.
C2	Choi, S.W., et al., "Design, Synthesis, and Biological Evaluation of Novel Non-Piperazine Analogues of 1-[2-(Dephenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-)3-phenylpropyl)piperazines as Dopamine Transporter Inhibitors," <i>J. Med. Chem.</i> , 42(18):3647-3656 (1999).
C3	Tsizin, Y.S., et al., "The structure and anthelmintic activity of tricyclic analogs of praziquantel and 4-acyl-2-piperazinones," retrieved frm STN Database accession no. 117:39808.

Applicants have enclosed herewith copies of each document cited above. These references were cited in the November 7, 2000 International Search Report (copy enclosed) issued in the counterpart International Application No. PCT/US 00/18577 filed July 6, 2000.


Applicants request that these documents: (1) be fully considered by the Examiner during examination of this application, and (2) be printed on any patent that may issue from this application.

A completed Form PTO-1449 listing all of the documents is enclosed herewith in duplicate. Applicants also request that a copy of the enclosed Form PTO-1449 duly initialed by the Examiner be forwarded to the undersigned with the next communication.

This Information Disclosure Statement is being submitted more than three months after the filing date but before the mailing of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee.

The Director is, however, hereby authorized to charge to Deposit Account No. 50-0725 payment of any fees required in connection with the accompanying Information Disclosure Statement. A duplicate copy of this statement is transmitted herewith.

Respectfully submitted,



---

Nandakumar Govindaswamy  
Limited Recognition  
Attorney for Applicants  
c/o VERTEX PHARMACEUTICALS  
INCORPORATED  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel.: (617) 444-6467  
Fax: (617) 444-6483



VPI/98-19 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned  
Group Art Unit : 1646  
Applicants : David Lauffer, et al.  
Application No.: 10/039,898  
Filed : January 3, 2002  
For : CYCLIZED AMINO ACID DERIVATIVES

Cambridge, Massachusetts  
October 15, 2002

Hon. Commissioner  
for Patents  
Washington, D.C. 20231

RECEIVED  
OCT 22 2002  
TECH CENTER 1600/2900

TRANSMITTAL LETTER FOR  
INFORMATION DISCLOSURE STATEMENT

Sir:


Transmitted herewith is an Information Disclosure Statement in the above-identified application. This Statement is submitted:

- ☐ [ ] within three months of the application filing date;
- ☒ [X] more than three months from the application filing date but before the mailing date of the first Office Action on the merits.

In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with

this Information Disclosure Statement to Deposit Account  
No. 06-1075. A duplicate copy of this letter is  
transmitted herewith.

Respectfully submitted,



---

Nandakumar Govindaswamy  
Limited Recognition  
Attorney for Applicants  
c/o VERTEX PHARMACEUTICALS  
INCORPORATED  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel.: (617) 444-6467  
Fax: (617) 444-6483